Therapeutic Effects of Topical Doxycycline in a Benzalkonium Chloride-Induced Mouse Dry Eye Model

doxycyclineBenzalkonium chloride (BAC) has been a culprit in the ongoing battle of treating patients ocular surface disease (OSD). When patients must be treated for glaucoma and other conditions in which the topical regimen has this preservative included in the formulation, many suffer deleterious effects from the drug.

Those with dry eye disease (DED) have a compounded effect that adds insult to injury. An interesting pre-publication in Investigative Ophthalmology & Visual Science (IOVS) by Zhang et al titled “Therapeutic Effects of Topical Doxycycline in a Benzalkonium Chloride-Induced Mouse Dry Eye Model” presents an interesting study of a possible treatment option in the future for our patients. We have seen positive effects of oral doxycycline in patients having meibomian gland dysfunction (MGD) and this study is a novel approach which includes evaluation of tear break-up time (BUT), fluorescein staining, inflammatory index, and tear volume were performed on Day 0, 1, 4, 7, and 10. Eye drops containing 0.025%, 0.1% doxycycline or solvent were administered to a BAC-induced dry eye model four times daily. Here are a few of the results: improvements in decreasing fluorescein staining scores, increasing Ki-67 positive cells, and decreasing TUNEL and keratin-10 positive cells than other groups. The mucin-filled goblet cells in conjunctivas were increased, and the expression of CD11b and levels of matrix metalloproteinase-9, interleukin (IL)-1β, IL-6, tumor necrosis factor-α, macrophage inflammatory protein-2, and cytokine-induced neutrophil chemoattractant in corneas were decreased in both doxycycline-treated groups. Wow, could this be the next blockbuster drug that might be able to obtain FDA approval or should it be something to consider simply having formulated at a compounding pharmacy?

Read more here.

Authors: Zhang Z1, Yang WZ, Zhu ZZ, Hu QQ, Chen YF, He H, Chen Y, Liu ZG.

Over 1,000 Patients Reveal Their Confidence in Tear Osmolarity Testing

Tear Osmolarity Testing

Last July, TearLab partnered with the Sjögren's Society to help promote Dry Eye Disease Awareness Month. During the month, TearLab surveyed patients who were tested with the TearLab Osmolarity System. Ophthalmic Consultants of Long Island were … [Continue reading]

The Hormone-Dry Eye Connection, Part 2

Insulin warning message background

How closely do you evaluate your diabetics for dry eye disease (DED)? We have known for decades to watch for glaucoma and diabetic retinopathy which obviously are critically important. However, recently more and more research is showing the … [Continue reading]

How to Incorporate Tear Osmolarity Testing Into Practice

the cedars supp.fw

Recently, a panel of ophthalmologists from the Cornea, External Disease, and Refractive Society (CEDARS) convened to discuss the impact of dry eye disease on clinical practice. Because ocular surface dryness is so prevalent among cataract and … [Continue reading]

A model for tear film thinning with osmolarity and fluorescein

right eye man

As we learn more and more about the design of our tear film it continues to be understood as an exquisite structure that provides not only protection but ensures clear consistent vision when in homeostasis; and conversely can decrease in quality and … [Continue reading]

Comparison of Ocular Surface Disease Index and Tear Osmolarity as Markers of Ocular Surface Dysfunction in Video Terminal Display Workers.

dry eye disease visual display terminal

Anyone who sees patients that spend many hours per day on a video display terminal (VDT) knows more and more are having issues of dry eye disease (DED).  With the decrease in blinking and low office humidity these patients can present with … [Continue reading]

A Multicenter, Open-Label, 52-Week Study of 2% Rebamipide Ophthalmic Suspension in Patients with Dry Eye

Photo of young woman dripping eye with eyes drops

The search continues to find the holy grail in management of dry eye disease (DED).  More than a decade has passed since the approval of Restasis (cyclosporine A) in the United States. An article "in press" in the American Journal of Ophthalmology … [Continue reading]

Investigation of Tear Osmolarity Using the TearLab Osmolarity System in Normal Adults in Saudi Arabia

TearLab photo

More and more dry eye disease (DED) is being diagnosed using the TearLab Osmolarity System.  Understanding the disease is critical and tear osmolarity provides evidence of tear film instability when a patient’s tear osmolarity is elevated above … [Continue reading]

Why Dry Eye Trials Often Fail


"Tear osmolarity and ocular surface changes in patient with polycystic ovary syndrome” by Conen et al in a recent edition of Current Eye Research present some interesting findings regarding dry eye disease (DED) and symptoms.    Their findings … [Continue reading]

Visual Performance and the Ocular Surface in Traumatic Brain Injury


Dry eye disease (DED) is not the first thing you think of when yo hear of traumatic brain injury (TBI).  However, in a recent publication in Ocular Surface titled  "Visual performance and the ocular surface in traumatic brain injury.” by Cockerham et … [Continue reading]